Wang Zhiren, Li Henan
Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Cell Infect Microbiol. 2024 Nov 20;14:1471469. doi: 10.3389/fcimb.2024.1471469. eCollection 2024.
Tigecycline, hailed as a pivotal agent in combating multidrug-resistant bacterial infections, confronts obstacles posed by the emergence of resistance mechanisms in Gram-negative bacilli. This study explores the complex mechanisms of tigecycline resistance in Gram-negative bacilli, with a particular focus on the role of efflux pumps and drug modification in resistance. By summarizing these mechanisms, our objective is to provide a comprehensive understanding of tigecycline resistance in Gram-negative bacilli, thereby illuminating the evolving landscape of antimicrobial resistance. This review contributes to the elucidation of current existing tigecycline resistance mechanisms and provides insights into the development of effective strategies to manage the control of antimicrobial resistance in the clinical setting, as well as potential new targets for the treatment of tigecycline-resistant bacterial infections.
替加环素被誉为对抗多重耐药细菌感染的关键药物，但革兰氏阴性杆菌中耐药机制的出现给它带来了挑战。本研究探讨革兰氏阴性杆菌中替加环素耐药的复杂机制，特别关注外排泵和药物修饰在耐药中的作用。通过总结这些机制，我们的目标是全面了解革兰氏阴性杆菌中的替加环素耐药情况，从而阐明抗菌药物耐药性的演变态势。本综述有助于阐明当前现有的替加环素耐药机制，并为制定有效的策略以控制临床环境中的抗菌药物耐药性提供见解，同时也为治疗耐替加环素细菌感染提供潜在的新靶点。
